Association between Early Antibiotic Therapy and In-Hospital Mortality among Older Patients with SARS-CoV-2 Pneumonia

Alain Putot, MD, PhD1; Kevin Bouiller, MD, PhD2; Caroline Laborde, MD3; Marine Gilis, MD4; Amélie Fèvre, MD5; Arthur Hacquin, MS, MSc1; Patrick Manckoundia, MD, PhD1; Florence Hoefler, MD2; Messaline Bermejo, MD5; Aline Mendes, MD, PhD6; Christine Serratrice, MD, 7; Virginie Prendki, MD7,8; Stéphane Sanchez, MD, PhD9.

1 Department of Geriatric Internal Medicine, Dijon University Hospital, Dijon, France
2 Department of Infectious Diseases, Besançon University Hospital, Besançon, France
3 Department of Geriatric Internal Medicine, Nimes University Hospital, Nimes, France
4 Department of Geriatrics, Besançon University Hospital, Besançon, France
5 Department of Internal Medicine and Infectious Diseases, Troyes Hospital Centre, Troyes, France
6 Division of Geriatrics, University Hospitals of Geneva, Geneva, Switzerland
7 Division of Internal Medicine for the aged, University Hospitals of Geneva, Geneva, Switzerland
8 Division of Infectious Diseases, University Hospitals of Geneva, Geneva, Switzerland
9 Department of Clinical Research, Troyes Hospital Centre, Troyes, France

© The Author(s) 2021. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Corresponding author: Alain PUTOT, MD, PhD,

Service de Médecine Interne Gériatrie

Hôpital de Champmaillot CHU, 21079 Dijon Cedex, France

Phone: 00 333 80 29 39 70 Fax: 00 333 80 29 39 36 21

Email: alain.putot@chu-dijon.fr
ABSTRACT

**Background:** It is uncertain whether antibiotic therapy should be started in SARS CoV-2 pneumonia. We aimed to investigate the association between early antibiotic therapy and the risk of in-hospital mortality in older patients.

**Methods:** We performed a retrospective international cohort study (ANTIBIOVID) in five COVID-19 geriatric units in France and Switzerland. Among 1,357 consecutive patients aged 75 or more hospitalised and testing positive for SARS-CoV-2, 1,072 had a radiologically confirmed pneumonia, of which 914 patients were still alive and hospitalized at 48 hours. To adjust for confounders, a propensity score for treatment was created, and stabilized inverse probability of treatment weighting (SIPTW) was applied. To assess the association between early antibiotic therapy and in-hospital 30-day mortality, SIPTW-adjusted Kaplan-Meier and Cox proportional hazards regression analyses were performed.

**Results:** Of the 914 patients with SARS-CoV-2 pneumonia, median age of 86, 428 (46.8%) received antibiotics in the first 48 hours after diagnosis. Among these patients, 147 (34.3%) died in hospital within one month vs 118 patients (24.3%) with no early antibiotic treatment. After SIPTW, early antibiotic treatment was not significantly associated with mortality (adjusted hazard ratio, 1.23; 95% CI, 0.92-1.63; \( P = .160 \)). Microbiologically confirmed superinfections occurred rarely in both groups (bacterial pneumonia: 2.5% vs 1.5%, \( P = .220 \); blood stream infection: 8.2% vs 5.2%, \( P = .120 \); *Clostridioides difficile* colitis: 2.4% vs 1.0%, \( P = .222 \)).

**Conclusions:** In a large multicentre cohort of older inpatients with SARS-CoV-2 pneumonia, early antibiotic treatment did not appear to be associated with an improved prognosis.

**Keywords:** COVID-19; superinfection; co-infection; bacterial; bacteraemia
INTRODUCTION

The COVID-19 pandemic is the most deadly outbreak worldwide since the Spanish influenza pandemic in 1918, and its burden has been particularly heavy in the older population. Nearly one third of older patients hospitalized with SARS-CoV2 pneumonia died in hospital (1–3). Most deaths are the result of respiratory failure linked to viral pneumonia, for which therapeutic management is still a matter of debate. However, the distinction between bacterial and viral pneumonia remains particularly difficult in practice, and influenza experience has shown that coinfections are not rare in viral pneumonia, especially in older individuals (4). Despite recent advances in this field (5), there is currently no distinctive tool to conclusively distinguish SARS-CoV-2 pneumonia from bacterial pneumonia. Because delayed antibiotic treatment has been associated with worse outcomes in bacterial pneumonia (6), empirical antibiotic treatment was initially recommended for COVID-19 pneumonia in many guidelines (7). Since then, increasing data have highlighted a very low frequency of documented bacterial co- or superinfection in COVID-19 (8–14). Moreover, the widespread use of empirical antibiotics during the current pandemic appears to have contributed to the development of multidrug-resistant microorganisms (15–17). Thus, the most recent guidelines consensually suggest a restrictive use of antibacterial drugs in patients with COVID-19 (10,18–20). However, the level of evidence for such recommendations remains very low and repose on small-scale observational data (3,21–23). Interventional studies only focused on azithromycin and failed to demonstrate any benefit compared with usual care (24–26). Antibiotics remain still widely prescribed in practice (8,9,15), especially in frail older individuals (3,27).

To our knowledge, whether systemic antibiotic therapy should be prescribed in older patients with acute pneumonia and testing positive for COVID-19 has not yet been evaluated on a large scale. In a pilot study of older comorbid inpatients presenting with a SARS-CoV-2 pneumonia, we showed that one-month mortality did not differ whether patients received antibiotic treatment or not (3). We aimed to confirm this result in a larger multicenter cohort study.
METHODS

Data Source and Design

We performed a retrospective, multicenter cohort study using hospital records data from acute geriatric care units from four university hospitals and one regional hospital in France and Switzerland, during the first two waves of COVID-19 pandemic in Europe, from March 1, 2020, to December 31, 2020. Data were extracted from medical records in each hospital and anonymized before release to investigators.

This observational study was conducted in accordance with the Declaration of Helsinki and national standards. Geneva’s committee for research ethics was consulted and approved the study. Each participant or his/her referee received an information letter and was invited to express his/her opposition to participation in the study.

Patients

We included all consecutive patients aged 75 years or older presenting with acute, radiologically-confirmed pneumonia and testing positive for SARS-CoV-2 with real-time polymerase chain reaction (RT-PCR). Acute pneumonia was defined according to the American guidelines (28), in the acute presence of 2 or more of the following signs: new cough, sputum production, dyspnea, pleuritic pain, abnormal temperature (<35.6°C or >37.8°C), or altered breathing sounds on auscultation, and a new infiltrate on chest imaging.

We excluded patients who were discharged or died within 48 hours after admission or for whom a bacterial co-infection requiring antibiotics was documented at admission (i.e. positive culture results in the presence of suggestive clinical features).
Based on our previous studies (36% in-hospital mortality rate, 2/1 exposed/non exposed ratio) (2,3) and considering a 0.7 relative hazard as clinically significant, a total sample size of 847 patients was estimated to provide 80% power, using a 2-tailed hypothesis at an α level of .05.

**Exposure and Primary Outcome Measure**

We compared patients who received early systemic antibiotic treatment, i.e. within the first 48 hours after diagnosis, with those who did not receive any antibiotic in these first 48 hours. The primary outcome was in-hospital 30-day mortality.

**Data collection and management**

We recorded the following characteristics as potential confounders at admission:

Hospital centre, age, sex, underlying diseases and Charlson comorbidity index (29), clinical presentation (delay between symptom onset and positive RT-PCR test, heart rate, systolic and diastolic blood pressure, temperature, oxygen saturation, oxygen flow, respiratory rate, confusion) biological parameters (leucocyte count, C-reactive protein, albumin, urea, creatinine), prognosis scores (WHO severity class (18), CURB65 (30), Pneumonia severity index (31), NEWS2 (32), quickSOFA (33)). Place of acquisition of pneumonia was also recorded: community-acquired pneumonia (CAP), nursing-home-acquired pneumonia (NHAP) and late-onset hospital-acquired pneumonia (HAP), defined as symptom onset occurring after 4 days of hospitalization (34).

In-hospital management, including acute treatments (corticosteroid therapy with a daily dose ≥ 6mg of dexamethasone or equivalent (35), tocilizumab, remdesivir, lopinavir/ritonavir, chloroquine), antibiotic treatment (class: cephalosporins, penicillin with betalactamase inhibitors, macrolides, fluoroquinolones, and duration of first-line treatment) and palliative treatment (morphine,
midazolam), as well as superinfections occurring during hospital stay (suspected bacterial pneumonia and microbiologically confirmed pneumonia, bloodstream infection, urinary tract infections and *Clostridioides difficile* colitis) were reported. Confirmed superinfection was defined as any infection with clinical features and a positive microbiological sampling (blood cultures, sputum or aspiration cultures or positive serology for *Chlamydia pneumoniae*, urine cultures, positive enzyme immunoassay or PCR for *C. difficile* toxin). Suspected bacterial pneumonia was defined as a clinical suspicion of superinfection leading to an antibiotic prescription during hospital stay.

Vital status at discharge, hospital length of stay, transfer to intensive care unit, and palliative care requirement were also recorded.

To avoid excluding patients with missing values for several of the potential confounders, multiple imputation was used to handle missing data (<10% for all covariates) that were assumed to be missing at random for all covariates. Missing values were imputed 10 times, by sampling from their posterior predictive distribution, conditional on the observed data. In all subsequent analyses, Rubin’s rules were applied to summarize the effect estimates and variances from the 10 different analyses across multiple imputed data sets (36).

**Statistical Analysis**

Continuous variables were described using medians and interquartile ranges, and categorical variables were described using frequencies and percentages. Wilcoxon rank sum, χ², and log-rank tests were used to evaluate the statistical significance of unadjusted continuous, categorical, and time-to-event data, respectively. All tests were 2-tailed, and a *P* value of less than .05 was considered statistically significant. Statistical analyses were performed using SPSS 21.0 (IBM Corp, Armonk, NY) and R 4.0.4 software (R Foundation for Statistical Computing, Vienna, Austria).
**Propensity Model**

Older patients who receive antibiotic treatment often have a more severe presentation than those who do not. To account for potential confounding in the association of antibiotic use and mortality, we created a propensity score for each patient and applied inverse probability weighting. The propensity score represented the predicted probability of receiving antibiotic treatment and was determined using a logistic regression model with 48-hour antibiotic use as the dependent variable and the aforementioned potential confounders at admission (listed in table 1) as the independent variables. Each patient’s propensity score was then used to create an inverse probability weight for that patient. Stabilized inverse probability of treatment weight (SIPTW) was then obtained by multiplying the inverse probability weight by the marginal probability of receiving the actual treatment received (i.e. early antibiotic treatment or not) (37). After adjusting for these weights, a propensity-weighted sample was thus created that was more balanced with respect to potential confounders included in the regression model.

Before assessing the outcome, we confirmed that the weighted sample was balanced using the following parameters: standardized difference, -0.15 to 0.15; and variance ratio, 0.5 to 2.0 (38). We examined overlap plots of the propensity scores by treatment group to ensure that the area of common support was adequate.

**Outcomes**

SIPTW-adjusted Kaplan-Meier curves were calculated to compare overall in-hospital 30-day survival between patients who received early antibiotic treatment and those who did not. We further fitted an SIPTW-adjusted Cox proportional hazards regression model to compute the corresponding hazard ratio (HR). To avoid informative censoring, patients discharged from hospital were regarded as surviving to 30 days.
RESULTS

Demographics and Characteristics

From March 1, 2020, to December 31, 2020, 1369 consecutive patients over 75 years of age and positive for SARS-CoV2 (RT-PCR) were hospitalized. Among them, 297 had no pneumonia at admission, 54 had microbiologically documented bacterial infection at admission (33 bloodstream infection, 21 bacterial pneumonia), 100 died or were discharged in the first 48 hours, and 4 refused to participate. Finally, 914 patients were eligible for analysis (Figure 1). The median age was 86 [81-90] years, and 448 patients (49.0%) were male.

A total of 428 patients (46.8%) received antibiotic treatment in the first 48 hours. There was wide variability in early antibiotic prescription rate among the 5 centers, ranging from 11.2% to 74.9%. Patient characteristics at admission are presented in Table 1. Age did not significantly differ between patients receiving early antibiotic treatment or not. Patients who received initial antibiotic treatment were more likely to be male (53.5% vs 45.1%, \( P = .011 \)) and to have community-acquired pneumonia (68.5% vs 48.1%, \( P < .001 \)) rather than nursing-home (17.8% vs 23.0%, \( P = .048 \)) or hospital-acquired pneumonia (14.1% vs 27.4%, \( P < .001 \)). Underlying diseases were equally frequent in both groups (Charlson Comorbidity index: 3 [2-5] vs 3 [1-5], \( P = .473 \)), but of different distribution: among patients under early antibiotic treatment, chronic heart failure (25.4% vs 32.5, \( P = .019 \)) and cognitive disorders (35.9% vs 42.7%, \( P = .037 \)) were less frequent, whereas chronic kidney disease (43.4% vs 30.7%, \( P < .001 \)) was more frequent.

Clinical presentation

Diagnosis of SARS-CoV-2 pneumonia was confirmed by a positive RT-PCR test within a median of 3 days [1-7] after symptom onset in both groups (Table 1). Clinical presentation at admission differed in the two groups, with a more severe presentation among patients with early antibiotic treatment: heart
rate (86 [76-98] vs 81 [76-98] beats per minute, \( P < .001 \)), respiratory rate (24 [20-29] vs 22 [20-26] breaths per minute, \( P < .001 \)) and temperature (37.8 [36.9-38.5] vs 37 [36.4-38]°C, \( P < .001 \)) were significantly more elevated.

Patients with early antibiotic treatment had a higher leucocyte count (6.90 [5.05-9.94] vs 6.39 [4.80-8.70] G/L, \( P = .004 \)) and C-reactive protein level (85 [38-140] vs 50 [21-98], \( P < .001 \)).

Severity score

The WHO severity scale, specifically developed to stratify COVID-19 risk (18), was more elevated in patients with early antibiotic treatment (S3: severe pneumonia for 51.6 vs 45.7% of patients, \( P < .001 \)), as was the NEWS2 score (32) (6 [4-8] vs 5 [3-7], \( P < .001 \)). Other prognostic tools in pneumonia (PSI (31), CURB65 (30)) and in sepsis (qSOFA (33)) did not significantly differ between the two groups (Table 1).

After SIPTW, the differences in the baseline covariates that were apparent in the overall sample were no longer present (Table 1 and eFigure in the Supplement).

Treatments in Hospital

The acute treatments used for SARS-CoV-2 pneumonia during the hospital stay are presented in Table 2. After SIPTW, they did not significantly differ between the two groups, except for antibiotics. Corticosteroids (daily dose \( \geq 6 \)mg of dexamethasone or equivalent) were as frequently prescribed in patients with or without early antibiotic treatment (38.8% vs 39.6%, \( P = .825 \)), as were palliative treatments (morphine: 37.4% vs 34.8%, \( P = .825 \); midazolam: 22.7% vs 24.4%, \( P = .601 \)).

Median duration of first line of antibiotics was 6 [5-8] days in the early treatment group. Two thirds of the patients without early antibiotic treatment received antibiotics later during their hospital stay.
Beta-lactams were the most frequent antibiotic prescriptions in both groups (cephalosporins 54.1% vs 38.8%, penicillins + betalactamase inhibitors 54.0% vs 39.5%, \( P < .001 \)) followed by macrolides (26.0% vs 23.1%, \( P = .335 \)) and fluoroquinolones (5.1% vs 2.5%, \( P = .047 \)).

Co-infections

In the SIPTW cohort, suspected bacterial pneumonia was twice as frequent during the hospital stay in patients with early antibiotic treatment (37.6% vs 20.3%, \( P < .001 \)). However, documented superinfections were rare in both groups (documented bacterial pneumonia: 2.5% vs 1.5%, \( P = .220 \); documented bloodstream infection: 8.2% vs 5.2%, \( P = .120 \)). *C. difficile* colitis infections were also rare in both groups (2.4% vs 1.0%, \( P = .222 \)).

Microbiological data are presented in Table 3 (unweighted cohort). Pneumococcal (3 patients) and staphylococcal (*Staphylococcus aureus*: 4 patients) superinfections were rare. Gram negative bacilli were the majority, both in bloodstream infections (*Escherichia coli*: 25 patients, *Pseudomonas aeruginosa*: 6 patients, other gram negative bacilli: 8 patients) and in documented bacterial pneumonia (*P. aeruginosa*: 4 patients, other gram negative bacilli: 5 patients). Bacterial superinfections occurred earlier in patients receiving early antibiotic treatment (1 [0-6] vs 8 [6-13] days for bloodstream infection, 6 [4-8] vs 2 [0-5] days for documented bacterial pneumonia, \( P < .001 \)).

Outcomes

SIPTW-adjusted HR for in-hospital 30-day mortality in patients with versus without early antibiotic treatment was 1.23 [0.92-1.63] (\( P = .160 \)). SIPTW-adjusted Kaplan-Meier curves are presented in Figure 2: in-hospital 30-day mortality did not significantly differ between the two groups (log-rank test, \( P = .190 \)).
After SIPTW, hospital stays were as long in patients with early antibiotic treatment as in those without (11 [7-18] vs 11 [6-20], P = .988). The in-hospital 30-day mortality rate did not significantly differ in the two groups (32.0% vs 27.7%, P = .155). Despite the high mortality rate, transfer to intensive care unit was rare (5.7% vs 6.5%, P = .524) and patients often received palliative care (24.5% vs 19.4%, P = .099).

DISCUSSION

Antibiotics are undoubtedly one of the most important advances in medicine, even though the inappropriate use of these drugs threatens their effectiveness. There has been considerable concern about the widespread use of antibiotics since the beginning of the COVID-19 pandemic. Many authors have detected an increase in highly resistant pathogens and plead for raised antimicrobial stewardship efforts (14–17). However, the clinical presentation of severe COVID-19 is frequently indistinguishable from bacterial or fungal sepsis. Given the paucity of active therapeutics, physicians are often tempted to prescribe antibiotics in frail older patients with a severe presentation. Thus, there is a need for a higher level of evidence to support recent guidelines (10,18–20) against systematic antibiotic treatment in SARS-CoV-2 pneumonia, especially in the geriatric setting.

Few interventional studies have assessed the usefulness of antibiotic treatment in COVID-19. All trials comparing azithromycin to usual care failed to demonstrate any benefit of this antibiotic treatment (24–26). To the best of our knowledge, there is to date no interventional data concerning other antibiotic treatments. In particular, recommended empirical antibiotics for acute pneumonia (34,39), which are widely used in SARS-CoV-2 pneumonia (9), have not been evaluated in interventional studies nor in large observational studies.

The main results of this large multicenter cohort are as follows: 1) the in-hospital mortality rate for older patients hospitalized with SARS-CoV-2 pneumonia was nearly 30% at 30 days; 2) half of patients received early antibiotic treatment at admission; 3) bacterial superinfection during hospital
stay was seldom documented in patients with or without early antibiotic therapy; and 4) early antibiotic treatment was not associated with a better in-hospital prognosis.

Our results are consistent with the literature, highlighting that more than 70% of patients with SARS-CoV-2 infection receive antibiotics, but less than 10% experience bacterial and fungal coinfection (8,11,12). However, antibiotic use varies considerably from one center to another (8,9,40), as highlighted in our study (from 11.2% to 74.9% of patients), stressing the need for stronger evidence on this issue. Broad-spectrum therapies, mainly beta-lactams, were frequently prescribed, as recommended in recent guidelines for bacterial pneumonia (34,39). Contrary to other reports (9,11), macrolides were a minority of antibiotic prescriptions. As in other reports, we found that the likelihood of early antibiotic prescription was correlated with the initial severity of pneumonia, rather than with comorbidities (21). In this elderly population, age was no longer a criterion for early antibiotic prescription.

Here, one interesting result is the relatively high frequency of bloodstream infections compared with previous reports in younger patients (12,41), although they may have been slightly overestimated by blood culture contaminations (DNase negative *staphylococci*) (41). Our study population was expected to be at higher risk for severe superinfections for several reasons. First, older patients have already shown to be more prompt to develop superinfections during COVID-19 (42). Second, COVID-19 could particularly predispose to bacterial infection since bacteremia was found to be more frequent in COVID-19 than non-COVID-19 critically ill patients (43). This risk may be higher than in other infections: patients with COVID-19 were 2.5 times more likely to develop bacteremia than patients with influenza (44). The reasons for such a high frequency are not elucidated. However, the high frequency of *Enterobacteriaceae, Enterococci* and *Candida*, already documented by others in COVID-19 (9,11,14,45,46), suggest a potential digestive translocation (47), as already described at the acute phase of bacterial pneumonia (48). Digestive involvement is frequent in COVID-19 patients, especially in the older population (49), and could be due to ischemic damage in the gastrointestinal tract rather than direct viral damage (47). Interestingly, *C. difficile* colitis was rare, as also already reported by others. Even if antibiotic treatment remains a major risk factor for *C. difficile* infection in
COVID-19 inpatients (50), this low rate could be due to COVID-19-linked reinforced cleaning procedures and reduced patient mobility (51).

Whether systematic early antibiotic treatment should be introduced in the early phase of SARS-CoV2 pneumonia remains a current issue. In a recent single-center study, authors showed that early administered antibiotics did not impact mortality in critically ill patients with COVID-19 (22), confirming similar results in non-critically ill units (3,21). However these previous results did not have sufficient power to adequately assess this question. We believe that our large multicenter data further reinforce previous findings and strongly discourage systematic antibiotic treatment. Further research is needed to define the patients for whom antibiotics should be indicated and in which settings. Our results also show that documented bacterial superinfections often develop a week or more after COVID-19 diagnosis (median of 8 days) in patients without early antibiotic treatment, further mitigating the benefit of a systematic strategy. Some authors suggest that antibiotic therapy should be reserved for the patients with the most severe presentations (10,52), but no data to date support this position. Biomarkers (C-reactive protein, procalcitonin) may play a role in deciding when antibiotics can be withheld (5,46). Also, the ability of thoracic computed tomography to distinguish alveolar infiltrates associated with bacterial pneumonia as opposed to the typical glass ground opacities seen in COVID-19 remains to be evaluated (10).

This study has some limitations. First, only patients with COVID-19 hospitalized in a medical ward were included, and those initially hospitalized in the ICU were not considered. These results cannot be extrapolated to more severe patients, especially those under mechanical ventilation. Second, because no systematic sampling procedure was performed in these wards (screening was based on clinical judgment), microbiological documentation was often missing in this retrospective study. Thus, we probably underestimated bacterial infection occurrence. However, we believe that this study represents the real-world situation in most hospitals. Third, most of patients in the group without early antibiotic treatment during the first 48 hours did receive antibiotics later during their hospital stay.
This could have potentially mitigated any antibiotic benefit effect in the early treatment group. Again, this situation was expected in a very elderly hospital population with comorbidities. However, patients without any antibiotic treatment during hospital stay had a crude lower mortality rate (19.5%) than patients with early (34.4%) and delayed antibiotic treatment (28.0%), suggesting no benefit of such treatment. Fourth, even with an adjustment on comorbidities and clinical parameters at admission, including usual prognostic criteria in COVID-19, the results could be biased by unmeasured confounding due to factors such as frailty, which might not be well captured in routinely collected data. This study remains observational and only a randomized clinical trial could support a definite statement.

In this large multicenter study, half of older patients hospitalized with SARS-CoV-2 pneumonia received early antibiotic treatment after diagnosis even though no bacterial co-infection was documented. The likelihood of early antibiotic prescription was correlated with pneumonia severity rather than comorbidities. After adjustment for confounders, early antibiotic treatment was not associated with a decrease in in-hospital mortality or with superinfection occurrence. According to these data, antibiotic therapy should not be prescribed systematically for older patients with SARS-CoV2. Further investigations are required to target patients most at risk of bacterial superinfection, and interventional studies are needed to confirm these observational findings.
Funding: None declared.

Conflict of interests

All authors declare no competing interests.

Acknowledgments: We thank Sylvia Rostoix, Michèle Vouc’h, Sylvie Leconte for the data collection and Suzanne Rankin for the English review of the manuscript. They were not compensated for their contributions.

Author Contributions: Alain Putot and Stéphane Sanchez had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Alain Putot, Virginie Prendki

Acquisition, analysis, or interpretation of data: Alain Putot

Critical revision of the manuscript for important intellectual content: All authors

Statistical analysis: Alain Putot, Arthur Hacquin

Study supervision: Stéphane Sanchez.

Data sharing

The study protocol and the individual, de-identified patient data that underlie the results reported in this Article (text, tables, figures) are available on reasonable request from the corresponding author (AP; alain.putot@chu-dijon.fr) under certain conditions (with the consent of all participating centres and with a signed data access agreement).
REFERENCES

1. Zerah L, Baudouin É, Pépin M, et al. Clinical Characteristics and Outcomes of 821 Older Patients With SARS-Cov-2 Infection Admitted to Acute Care Geriatric Wards. Newman AB, ed. The Journals of Gerontology: Series A. August 2020:glaa210. doi:10.1093/gerona/glaa210.

2. Mendes A, Serratrice C, Herrmann FR, et al. Predictors of In-Hospital Mortality in Older Patients With COVID-19: The COVIDAge Study. Journal of the American Medical Directors Association. 2020;21(11):1546-1554.e3. doi:10.1016/j.jamda.2020.09.014.

3. Odille G, Girard N, Sanchez S, et al. Should we Prescribe Antibiotics in Older Patients Presenting COVID-19 Pneumonia? Journal of the American Medical Directors Association. December 2020:S1525861020310203. doi:10.1016/j.jamda.2020.11.034.

4. Metersky ML, Masterton RG, Lode H, File TM, Babinchak T. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis. 2012;16(5):e321-331. doi:10.1016/j.ijid.2012.01.003.

5. Mason CY, Kanitkar T, Richardson CJ, et al. Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics. J Antimicrob Chemother. January 2021. doi:10.1093/jac/dkaa563.

6. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997;278(23):2080-2084.
7. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. *Clin Infect Dis*. April 2020. doi:10.1093/cid/ciaa478.

8. Karami Z, Knoop BT, Dofferhoff ASM, et al. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands. *Infectious Diseases*. October 2020:1-9. doi:10.1080/23744235.2020.1839672.

9. Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. *Clin Infect Dis*. May 2020. doi:10.1093/cid/ciaa530.

10. Sieswerda E, de Boer MGJ, Bonten MMJ, et al. Recommendations for antibacterial therapy in adults with COVID-19 - an evidence based guideline. *Clin Microbiol Infect*. October 2020. doi:10.1016/j.cmi.2020.09.041.

11. Garcia-Vidal C, Sanjuan G, Moreno-García E, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. *Clin Microbiol Infect*. 2021;27(1):83-88. doi:10.1016/j.cmi.2020.07.041.

12. Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. *Clinical Microbiology and Infection*. 2020;26(12):1622-1629. doi:10.1016/j.cmi.2020.07.016.

13. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. *J Infect*. 2020;81(2):266-275. doi:10.1016/j.jinf.2020.05.046.
14. Nori P, Cowman K, Chen V, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. *Infect Control Hosp Epidemiol*. 2021;42(1):84-88. doi:10.1017/ice.2020.368.

15. Chong WH, Saha BK, Ananthakrishnan Ramani null, Chopra A. State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia. *Infection*. March 2021. doi:10.1007/s15010-021-01602-z.

16. Gomez-Simmonds A, Annavajhala MK, McConville TH, et al. Carbapenemase-producing Enterobacterales causing secondary infections during the COVID-19 crisis at a New York City hospital. *Journal of Antimicrobial Chemotherapy*. 2021;76(2):380-384. doi:10.1093/jac/dkaa466.

17. O’Toole RF. The interface between COVID-19 and bacterial healthcare-associated infections. *Clin Microbiol Infect*. June 2021:S1198-743X(21)00297-4. doi:10.1016/j.cmi.2021.06.001.

18. Clinical management of COVID-19. https://www.who.int/publications-detail-redirect/clinical-management-of-covid-19. Accessed November 6, 2020.

19. Mussini C, Falcone M, Nozza S, et al. Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). *Clin Microbiol Infect*. 2021;27(3):389-395. doi:10.1016/j.cmi.2020.12.011.

20. National Institute for Health and Clinical Excellence. COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital. https://www.nice.org.uk/guidance/ng173.
21. Moretto F, Sixt T, Devilliers H, et al. Is there a need to widely prescribe antibiotics in patients hospitalized with COVID-19? *Int J Infect Dis*. 2021;105:256-260. doi:10.1016/j.ijid.2021.01.051.

22. Buetti N, Mazzuchelli T, Lo Priore E, et al. Early administered antibiotics do not impact mortality in critically ill patients with COVID-19. *Journal of Infection*. 2020;81(2):e148-e149. doi:10.1016/j.jinf.2020.06.004.

23. Chedid M, Waked R, Haddad E, Chetata N, Saliba G, Choucair J. Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy. *J Infect Public Health*. 2021;14(5):570-576. doi:10.1016/j.jiph.2021.02.001.

24. PRINCIPLE Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *Lancet*. 2021;397(10279):1063-1074. doi:10.1016/S0140-6736(21)00461-X.

25. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet*. 2021;397(10274):605-612. doi:10.1016/S0140-6736(21)00149-5.

26. Furtado RHM, Berwanger O, Fonseca HA, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. *The Lancet*. 2020;396(10256):959-967. doi:10.1016/S0140-6736(20)31862-6.

27. Dieringer TD, Furukawa D, Graber CJ, et al. Inpatient antibiotic utilization in the Veterans Administration during the COVID-19 pandemic. *Infect Control Hosp Epidemiol*. October 2020;1-9. doi:10.1017/ice.2020.1277.
28. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med.* 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST.

29. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987;40(5):373-383.

30. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax.* 2003;58(5):377-382.

31. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. *New England Journal of Medicine.* 1997;336(4):243–250.

32. Scott LJ, Redmond NM, Tavarez A, Little H, Srivastava S, Pullyblank A. Association between National Early Warning Scores in primary care and clinical outcomes: an observational study in UK primary and secondary care. *Br J Gen Pract.* 2020;70(695):e374-e380. doi:10.3399/bjgp20X709337.

33. Liu S, Yao N, Qiu Y, He C. Predictive performance of SOFA and qSOFA for in-hospital mortality in severe novel coronavirus disease. *The American Journal of Emergency Medicine.* 2020;38(10):2074-2080. doi:10.1016/j.ajem.2020.07.019.

34. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the
Infectious Diseases Society of America and the American Thoracic Society. *Clinical Infectious Diseases*. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353.

35. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report | NEJM. https://www.nejm.org/doi/full/10.1056/NEJMa2021436. Accessed November 6, 2020.

36. Granger E, Sergeant JC, Lunt M. Avoiding pitfalls when combining multiple imputation and propensity scores. *Statistics in Medicine*. 2019;38(26):5120-5132. doi:https://doi.org/10.1002/sim.8355.

37. Xu S, Ross C, Raebel MA, Shetterly S, Blanchette C, Smith D. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. *Value Health*. 2010;13(2):273-277. doi:10.1111/j.1524-4733.2009.00671.x.

38. Linden A, Samuels SJ. Using balance statistics to determine the optimal number of controls in matching studies. *J Eval Clin Pract*. 2013;19(5):968-975. doi:10.1111/jep.12072.

39. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. *American journal of respiratory and critical care medicine*. 2001;163(7):1730–1754.

40. Seaton RA, Gibbons CL, Cooper L, et al. Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. *Journal of Infection*. 2020;81(6):952-960. doi:10.1016/j.jinf.2020.09.024.

41. Yu D, Ininbergs K, Hedman K, Giske CG, Strålin K, Özenci V. Low prevalence of bloodstream infection and high blood culture contamination rates in patients with
COVID-19. Leekha S, ed. *PLoS ONE*. 2020;15(11):e0242533.
doi:10.1371/journal.pone.0242533.

42. Goncalves Mendes Neto A, Lo KB, Wattoo A, et al. Bacterial infections and patterns of antibiotic use in patients with COVID-19. *J Med Virol*. 2021;93(3):1489-1495.
doi:10.1002/jmv.26441.

43. Buetti N, Ruckly S, de Montmollin E, et al. COVID-19 increased the risk of ICU-acquired bloodstream infections: a case–cohort study from the multicentric OUTCOMEREA network. *Intensive Care Med*. 2021;47(2):180-187.
doi:10.1007/s00134-021-06346-w.

44. Cates J, Lucero-Obusan C, Dahl RM, et al. Risk for In-Hospital Complications Associated with COVID-19 and Influenza — Veterans Health Administration, United States, October 1, 2018—May 31, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(42):1528-1534. doi:10.15585/mmwr.mm6942e3.

45. Bonazzetti C, Morena V, Giacomelli A, et al. Unexpectedly High Frequency of Enterococcal Bloodstream Infections in Coronavirus Disease 2019 Patients Admitted to an Italian ICU: An Observational Study. *Crit Care Med*. 2021;49(1):e31-e40.
doi:10.1097/CCM.0000000000004748.

46. Wang L, Amin AK, Khanna P, et al. An observational cohort study of bacterial co-infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London. *Journal of Antimicrobial Chemotherapy*. 2021;76(3):796-803. doi:10.1093/jac/dkaa475.

47. Cardinale V, Capurso G, Ianiro G, Gasbarrini A, Arcidiacono PG, Alvaro D. Intestinal permeability changes with bacterial translocation as key events modulating systemic
host immune response to SARS-CoV-2: A working hypothesis. *Digestive and Liver Disease*. 2020;52(12):1383-1389. doi:10.1016/j.dld.2020.09.009.

48. Cangemi R, Della Valle P, Calvieri C, et al. Low-grade endotoxemia and clotting activation in the early phase of pneumonia. *Respirology*. 2016;21(8):1465-1471. doi:10.1111/resp.12854.

49. Annweiler C, Sacco G, Salles N, et al. National French survey of COVID-19 symptoms in people aged 70 and over. *Clin Infect Dis*. June 2020. doi:10.1093/cid/ciaa792.

50. Granata G, Bartoloni A, Codeluppi M, et al. The Burden of Clostridioides Difficile Infection during the COVID-19 Pandemic: A Retrospective Case-Control Study in Italian Hospitals (CloVid). *J Clin Med*. 2020;9(12). doi:10.3390/jcm9123855.

51. Ponce-Alonso M, Sáez de la Fuente J, Rincón-Carлавilla A, et al. Impact of the coronavirus disease 2019 (COVID-19) pandemic on nosocomial *Clostridioides difficile* infection. *Infect Control Hosp Epidemiol*. September 2020:1-5. doi:10.1017/ice.2020.454.

52. Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: don’t neglect antimicrobial stewardship principles! *Clinical Microbiology and Infection*. 2020;26(7):808-810. doi:10.1016/j.cmi.2020.04.024.
Table 1: Characteristics of Patients at Admission (n (%) or Median [interquartile range])

|                      | Unweighted Study Population | Weighted Study Population |
|----------------------|----------------------------|---------------------------|
|                      | Antibiotics | No Antibiotics | P  | Standardized Difference | Antibiotics | No Antibiotics | Standardized Difference |
|                      | N = 428      | N = 486          |    |                           | N = 428      | N = 486          |                           |
| Hospital Centre      |             |                 |    |                           |             |                 |                           |
| Centre (1)           | 135 (31.5)  | 126 (25.9)      | <.001 | .124 | 29.8 | 28.7 | .024 |
| Centre (2)           | 63 (14.7)   | 110 (22.6)      | -.205 | 20.9 | 19.3 | .040 |
| Centre (3)           | 82 (19.2)   | 94 (19.3)       | -.003 | 19.7 | 20.0 | -.008 |
| Centre (4)           | 14 (3.3)    | 111 (22.8)      | -.619 | 9.3  | 13.6 | -.135 |
| Centre (5)           | 134 (31.3)  | 45 (9.3)        | .561 | 20.3 | 18.4 | .048 |
| Demographics         |             |                 |    |                           |             |                 |                           |
| Age (years)          | 85.7 [80.9-90.6] | 86.2 [81.5-90.2] | .655 | -.039 | 86.2 [81.4-90.8] | 86.1 [81.3-90.1] | .035 |
| Male                 | 229 (53.5)  | 219 (45.1)      | .011 | .169 | 51.1 | 48.9 | .044 |
| Community-acquired pneumonia | 292 (68.2) | 241 (49.6)      | <.001 | .422 | 59.5 | 56.6 | .059 |
| Nursing-home-acquired pneumonia | 76 (17.8)  | 112 (23)        | -.129 | 22.6 | 22.8 | -.005 |
| Hospital-acquired pneumonia | 60 (14)    | 133 (27.4)      | -.330 | 17.8 | 19.9 | -.054 |
| Severity scores      |             |                 |    |                           |             |                 |                           |

Downloaded from https://academic.oup.com/biomedgerontology/advance-article/doi/10.1093/gerona/glab209/6323249 by guest on 18 July 2021
|                        | 120 [104-136] | 121 [103-143] | .536 | -.156 | 120 [105-136] | 120 [101-141] | .035 |
|------------------------|---------------|---------------|------|--------|---------------|---------------|------|
| Pneumonia Severity Index |               |               |      |        |               |               |      |
| CURB65 >2              | 192 (44.9)    | 208 (42.8)    | .531 | .328   | 45.1          | 45.3          | -.004 |
| NEWS2                  | 6 [4-8]       | 5 [3-7]       | <.001| .373   | 6 [4-8]       | 5 [4-7]       | .070 |
| qSOFA >1               | 73 (17.1)     | 82 (16.9)     | .941 | .005   | 18.2          | 17.4          | .021 |
| WHO score S2           | 150 (35.0)    | 200 (41.1)    | <.001| -.365  | 33.8          | 36.5          | -.012 |
| WHO score S3           | 221 (51.6)    | 222 (45.7)    | .118 |        | 52.1          | 49.6          | .050 |
| WHO score S4           | 57 (13.3)     | 64 (13.2)     | .003 |        | 14.1          | 13.9          | .006 |

**Underlying disease**

|                      | 107 (25.4)    | 153 (32.5)    | .019 | -.157  | 28.2          | 30.2          | -.044 |
|----------------------|---------------|---------------|------|--------|---------------|---------------|------|
| Chronic heart failure|               |               |      |        |               |               |      |
| Chronic respiratory disease | 62 (18.1)    | 82 (20.8)    | .360 | -.068  | 20.7          | 21.6          | -.022 |
| Chronic kidney disease | 183 (43.4)    | 147 (30.7)    | <.001| .266   | 36.7          | 35.8          | .019 |
| Chronic liver disease | 18 (4.2)      | 26 (5.4)      | .411 | -.056  | 3.9           | 5.0           | -.053 |
| Cognitive disorders   | 152 (35.9)    | 206 (42.7)    | .037 | -.139  | 39.5          | 39.9          | -.008 |
| Stroke                | 85 (20.2)     | 90 (18.8)     | .607 | .035   | 20.1          | 19.5          | .015 |
| Myocardial Infarction | 68 (15.9)     | 80 (16.5)     | .804 | -.016  | 15.6          | 16.5          | -.025 |
| Active Neoplasia      | 67 (15.8)     | 82 (17.1)     | .595 | -.035  | 16.9          | 16.7          | .005 |
### Diabetes

|                | 104 (24.6) | 130 (27) | .403 | -.055 | 24.7 | 24.6 | .002 |
|----------------|------------|----------|------|-------|------|------|------|

### PAD

|                | 45 (10.6)  | 80 (16.7) | .009 | -.179 | 14.0 | 14.8 | -.023 |

### Charlson Comorbidity index

|                | 3 [2-5]    | 3 [1-5]   | .473 | .063  | 3 [2-5] | 3 [1-4] | .016  |

### Clinical presentation

|                                |            |          |      |       |      |      |      |
|--------------------------------|------------|----------|------|-------|------|------|------|

### Delay symptoms – diagnosis* (days)

|                                | 3 [1-7]    | 3 [1-7]  | .541 | -.084 | 2 [1-6] | 2 [1-7] | -.016 |

### Heart rate (/min)

|                                | 86 [76-98] | 81 [71-94] | < .001 | .258 | 85 [75-97] | 84 [73-96] | .005  |

### SBP (mmHg)

|                                | 131 [117-144] | 133 [120-149] | .086 | -.100 | 131 [118-146] | 132 [119-148] | -.003 |

### DBP (mmHg)

|                                | 70 [62-78] | 71 [63-81] | .091 | -.058 | 70 [62-79] | 71 [63-80] | -.003 |

### Temperature (°C)

|                                | 37.8 [36.9-38.5] | 37 [36.4-38] | < .001 | .083 | 37.6 [36.8-38.3] | 37.2 [36.6-38] | .027 |

### O$_2$ Saturation (%)

|                                | 94 [92-96] | 94 [92-96] | .057 | -.099 | 94 [92-96] | 94 [92-96] | .005 |

### Oxygenation (L/min)

|                                | 0.5 [0-2]  | 0 [0-2]   | .301 | .042  | 1[0-2]    | 1 [0-2]   | .014 |

### Respiratory rate (/min)

|                                | 24 [20-29] | 22 [20-26] | < .001 | .793 | 25 [22-28] | 25 [21-28] | .007 |

### Confusion

|                                | 72 (16.8)  | 102 (23.9) | .109 | -.176 | 20.6 | 20.7 | -.002 |

### Biology

|                                |            |          |      |       |      |      |      |
|                                |            |          |      |       |      |      |      |

### Leucocytes (G/L)

|                                | 6.90 [5.05-9.94] | 6.39 [4.80-8.70] | .004 | .163  | 7.39 [5.10-9.20] | 7.00 [5.19-9.20] | .027 |

### Neutrophils (G/L)

|                                | 5.29 [3.68-7.77] | 4.60 [3.27-6.93] | .003 | .215  | 6.10 [3.84-7.02] | 5.40 [3.52-6.79] | .022 |
| Parameter                              | Mean [Min-Max] | Standard Deviation | Minimum [Min-Max] | Maximum [Min-Max] | p-value |
|----------------------------------------|----------------|--------------------|-------------------|-------------------|---------|
| Lymphocytes (G/L)                      | 0.85 [0.57-1.27] | .180               | 0.93 [0.63-1.25]  | 1.02 [0.61-1.83]  | .036    |
| Platelets (G/mL)                       | 191 [153-261]   | .150               | 204 [152-279]     | 203 [156-253]     | .120    |
| C-reactive protein (mg/L)              | 85 [38-140]     | <.001              | 50 [21-98]        | 83 [38-116]       | .398    |
| Albumin (g/L)                          | 31 [27-36]      | .211               | 32 [28-36]        | 31 [29-34]        | .120    |
| Urea (mmol/L)                          | 9.0 [6.4-13.1]  | .352               | 8.5 [6-13.3]      | 9.3 [6.8-11.9]    | .086    |
| Creatinine (umol/L)                    | 91 [74-128]     | .049               | 89 [67-119]       | 97 [75-120]       | .007    |

DBP; Diastolic blood pressure; PAD: peripheral artery disease; SBP :systolic blood pressure; WHO: World Health Organisation

*Data are presented as number (percentage) of patients unless otherwise indicated.

Data are presented as percentage of patients unless otherwise indicated.

*delay between symptom onset and positive SARS-CoV2 Real-Time Polymerase Chain Reaction.
Table 2: In-hospital Management and Outcomes (n (%) or Median [interquartile range])

| Therapeutics                      | Unweighted Study Population<sup>a</sup> | Weighted Study Population<sup>b</sup> |
|-----------------------------------|----------------------------------------|---------------------------------------|
|                                   | Antibiotics N = 428 | No Antibiotics N = 486 | Antibiotics | No Antibiotics | P  | Antibiotics | No Antibiotics | P  |
| Therapeutics                      | 141 (32.9) | 198 (40.7) | .015 | 38.8 | 39.6 | .825 |
| Tocilizumab                       | 46 (10.7)  | 25 (9.3)  | .453 | 9.2  | 9.9  | .513 |
| Remdesivir                        | 46 (10.7)  | 37 (7.6)  | .100 | 8.3  | 9.1  | .657 |
| Lopinavir/ritonavir               | 71 (16.6)  | 39 (8.0)  | <.001 | 9.3  | .070 |
| Chloroquine                       | 65 (15.2)  | 56 (11.5) | .103 | 12.3 | 13.7 | .560 |
| Morphine                          | 144 (33.6) | 157 (32.3) | .667 | 37.4 | 34.8 | .420 |
| Midazolam                         | 82 (23.7)  | 77 (19.6) | .181 | 24.4 | 22.7 | .601 |
| Antibiotic treatment              | 428 (100)  | 297 (61.1) | <.001 | 66.1 | <.001 |
| Cephalosporin                     | 265 (61.9) | 135 (29.9) | <.001 | 38.8 | <.001 |
| Penicillin + inhibitor            | 201 (47.0) | 185 (41.0) | .076 | 54.0 | 39.5 | <.001 |
| Macrolide                         | 136 (31.8) | 78 (17.3)  | <.001 | 23.1 | .335 |
| Fluoroquinolone                   | 26 (6.1)   | 11 (2.4)   | .007 | 5.1  | 2.5  | .047 |
| First line of treatment length (days) | 6 [5-8]  | 1 [0-5]    | <.0016 | 2 [0-6] | <.001 |
| Co-infections                     | 147 (34.3) | 103 (21.2) | <.00137.6 | 20.3 | <.001 |
| Suspected bacterial pneumonia     | 10 (2.3)   | 6 (1.2)    | .205 | 2.5  | 1.5  | .220 |
| Documented bacterial pneumonia    | 44 (11)    | 18 (3.7)   | <.0018.2 | 5.2  | .120 |
| Blood stream infection            | 36 (8.4)   | 38 (7.8)   | .597 | 8.7  | 7.9  | .579 |
| Urinary tract infection           | 6 (1.4)    | 7 (1.4)    | .961 | 2.4  | 1.0  | .222 |
| C. difficile infection            | 6 (1.4)    | 7 (1.4)    | .961 | 2.4  | 1.0  | .222 |
| Outcomes                          | 428 (100)  | 297 (61.1) | <.001 | 66.1 | <.001 |

Downloaded from https://academic.oup.com/biomedgerontology/advance-article/doi/10.1093/gerona/glab209/6323249 by guest on 18 July 2021
|                                |       |       |       |       |       |
|--------------------------------|-------|-------|-------|-------|-------|
| **Length of hospital stay (days)** | 10 [7-17] | 12 [7-20] | .037 | 11 [7-18] | 11 [6-20] | .988 |
| **Transfer to intensive care unit** | 23 (4.5) | 29 (6.7) | .399 | 5.7 | 6.5 | .524 |
| **Palliative care requirement** | 72 (20.8) | 63 (16.1) | .097 | 24.5 | 19.4 | .099 |
| **30-day in-hospital death** | 147 (34.3) | 118 (24.3) | .001 | 32.0 | 27.7 | .155 |

aData are presented as number (percentage) of patients unless otherwise indicated.

bData are presented as percentage of patients unless otherwise indicated.

*Equivalent ≥ 6mg dexamethasone
| Table 3: Microbiological Documentation of In-hospital Superinfections (n or Median [Interquartile Range]) |
|----------------------------------------------------------|
| **Antibiotics** | **No Antibiotics** |
| **N = 428** | **N = 486** |
| **Blood stream infection** | | |
| Delay# (days) | 1 [0-6] | 8 [6-13] |
| *Escherichia Coli* | 18 | 7 |
| *Pseudomonas aeruginosa* | 4 | 2 |
| Other gram negative bacilli* | 5 | 3 |
| *Enterococcus spp.* | 3 | 2 |
| *Streptococcus spp.* | 4 | 0 |
| *Staphylococcus aureus* | 3 | 1 |
| Other staphylococcus | 8 | 4 |
| *Candida spp.* | 1 | 1 |
| **Pneumonia** | | |
| Delay# (days) | 2 [0-5] | 6 [4-8] |
| *Streptococcus pneumoniae* | 2 | 1 |
| *Pseudomonas aeruginosa* | 2 | 2 |
| *Serratia marcescens* | 0 | 1 |
| *Stenotrophomonas maltophilia* | 2 | 0 |
| *Enterobacter cloacae* | 1 | 0 |
| *Citrobacter freundii* | 1 | 0 |
| *Chlamydia pneumoniae* | 2 | 2 |

*Klebsiella pneumoniae (3), Klebsiella aerogenes, Proteus mirabilis, Serratia marcescens, Acinetobacter baumanii, Actinotignum shaali*

# delay between first positive SARS CoV2 real time polymerase chain reaction and positive bacterial sampling
Table titles and figure captions

**Table 1**: Characteristics of Patients at Admission (n(%) or median [interquartile range])

**Table 2**: In-hospital Management and Outcomes (n (%) or Median [interquartile range])

**Table 3**: Microbiological Documentation of In-hospital Superinfections (n or Median [Interquartile Range])

**Figure 1**:
Diagram of Patient Eligibility and Flow

**Figure 2**:
Propensity Score-Weighted 30-Day In-hospital Survival Curve for Older Patients Who Received Antibiotics versus No Antibiotics within the First 48 Hours of the Diagnosis of SARS-COV-2 Pneumonia
Figure 1

Patients ≥75 yrs, COVID+ n = 1369

No pneumonia
n = 257

Patients ≥75 yrs, COVID+ with pneumonia
n = 1072

Died / discharged within 48 h
n = 100

Documented bacterial infection at admission
n = 54

Refused to participate
n = 8

1072 patients included
n = 914

Patients with antibiotic treatment within 48 hours
n = 428

Patients without antibiotic treatment within 48 hours
n = 486
Figure 2

Log-rank test, $P = .190$